[13C]pantoprazole breath test as a predictor of the anti-platelet function of clopidogrel

European Journal of Clinical Pharmacology

Volumn 66, Issue 5, 2010, Pages 457-463

  Furuta, Takahisa ^a   Iwaki, Takayuki ^a   Umemura, Kazuo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

13C pantoprazole; Clopidogrel; CYP2C19; Platelet

Indexed keywords

CARBON 13; CARBON DIOXIDE; CLOPIDOGREL; CYTOCHROME P450 2C19; PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTITHROMBOCYTIC AGENT; CARBON; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; PHARMACOLOGICAL BIOMARKER; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEASIBILITY STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; DRUG EFFECT; GENETICS; METHODOLOGY;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOMARKERS, PHARMACOLOGICAL; BREATH TESTS; CARBON ISOTOPES; FEASIBILITY STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 77954487839     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0807-4     Document Type: Article

References (23)

1. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (9038): 1329-1339. doi:S0140673696094573 [pii]
2. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345(7):494-502
3. Chen MC, Hu CT, Wang LY, Lin HH (2005) The efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 22(3):274-275. doi:APT2545 [pii] 10.1111/j.1365-2036.2005.02545.x, author reply 275-276
4. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST- segment elevation. N Engl J Med 352(12):1179-1189. doi: NEJMoa050522 [pii] 10.1056/NEJMoa050522 (Pubitemid 40397259)
5. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, Novikov I, Pres H, Savion N, Varon D, Hod H (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109(25):3171-3175. doi:10.1161/01. CIR.0000130846.46168.03 [pii]
6. Gurbel PA, Bliden KP (2003) A new method of representing druginduced platelet inhibition: better description of time course, response variability, non-response, and heightened activity. Platelets 14(7-8):481-483. doi:10.1080/0269745031000163258883QH6KFECW85BXA7 [pii]
7. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45(2):246-251. doi:S0735-1097(04)02068-2076 [pii] 10.1016/j.jacc.2004.09.067 (Pubitemid 40094733)
8. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, Tantry US (2005) Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46(10):1827-1832. doi:S0735-1097(05)01993-1995 [pii] 10.1016/j.jacc.2005.07.056 (Pubitemid 41579803)
9. Umemura K, Furuta T, Kondo K (2008) The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 6(8):1439-1441. doi:JTH3050 [pii] 10.1111/j.1538-7836.2008.03050.x (Pubitemid 352016331)
10. Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, Faille D, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC (2008) Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronarysyndrome. Am J Cardiol 101(8):1088-1093. doi:S0002-9149(07)02447- 2452 [pii] 10.1016/j.amjcard.2007.11.065
11. Tanaka M, Ohkubo T, Otani K, Suzuki A, Kaneko S, Sugawara K,Ryokawa Y, Hakusui H, Yamamori S, Ishizaki T (1997) Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 62(6):619-628. doi:S0009-9236(97) 90081-3 [pii] 10.1016/S0009-9236(97)90081-90083
12. Desta Z, Modak A, Nguyen PD, Lemler SM, Kurogi Y, Li L, Flockhart DA (2009) Rapid identification of the hepatic cytochrome P450 (CYP) 2C19 activity using a novel and noninvasive [13C]-pantoprazole breath test. J Pharmacol ExpTher 329(1):297-305. doi:jpet.108.147751 [pii] 10.1124/jpet. 108.147751
13. Furuta T, Kodaira C, Nishino M, Yamade M, Sugimoto M, IkumaM, Hishida A, Watanabe H, Umemura K (2009) [13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole. Aliment Pharmacol Ther 30(3):294-300. doi:APT4044 [pii] 10.1111/j.1365-2036.2009.04044.x
14. Furuta T, Sagehashi Y, Shirai N, SugimotoM, Nakamura A, Kodaira M, Kenmotsu K, Nagano M, Egashira T, Ueda K, Yoneyama M, Ohashi K, Ishizaki T, Hishida A (2005) Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori Infection. Clin Gastroenterol Hepatol 3(6):564-573
15. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79(1):103-113
16. Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS, Jakubowski JA, Naganuma H, Winters KJ (2007) A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 153(1):66 e69-16. doi:S0002-8703(06)00902-911 [pii] 10.1016/j.ahj.2006.10.010 (Pubitemid 44895531)
17. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, PfefferMA, Taubert KA (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19):2363-2372. doi:113/19/2363 [pii] 10.1161/CIRCULATIONAHA.106.174516 (Pubitemid 43947981)
18. Caplan LR (2006) Antiplatelet therapy in stroke prevention: present and future. Cerebrovasc Dis 21(Suppl 1):1-6. doi: CED2006021S01001 [pii] 10.1159/000090356 (Pubitemid 43254155)
19. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (23):2908-2913. doi:10.1161/01.CIR.0000072771.11429.8301.CIR.0000072771.11429.83[pii]
20. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck- Brentano C, Montalescot G (2009) Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373(9660):309-317. doi:S0140-6736(08)61845-0 [pii] 10.1016/S0140-6736(08)61845- 61850
21. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2008) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. doi:NEJMoa0809171 [pii] 10.1056/NEJMoa0809171
22. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360(4):363-375. doi: NEJMoa0808227 [pii] 10.1056/NEJMoa0808227
23. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5(12):2429-2436. doi:JTH2775 [pii] 10.1111/j.1538-7836.2007.02775.x (Pubitemid 350154353)